Warning! GuruFocus detected
1 Severe warning sign
with AVIR.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Atea Pharmaceuticals Inc
NAICS : 541714
SIC : 2833
ISIN : US04683R1068
Share Class Description:
AVIR: Ordinary SharesDescription
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 276.93 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year FCF Growth Rate | -17.7 | |||||
| 3-Year Book Growth Rate | -15.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 10.01 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.13 | |||||
| 9-Day RSI | 63.49 | |||||
| 14-Day RSI | 58.42 | |||||
| 3-1 Month Momentum % | -3.38 | |||||
| 6-1 Month Momentum % | -8.45 | |||||
| 12-1 Month Momentum % | -17.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 24.85 | |||||
| Quick Ratio | 24.85 | |||||
| Cash Ratio | 24.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | 0.27 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -34.6 | |||||
| ROA % | -32.21 | |||||
| ROIC % | -4207.47 | |||||
| 3-Year ROIIC % | -12979.32 | |||||
| ROC (Joel Greenblatt) % | -7370.69 | |||||
| ROCE % | -39.06 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.62 | |||||
| Price-to-Tangible-Book | 0.62 | |||||
| EV-to-EBIT | 0.93 | |||||
| EV-to-EBITDA | 0.93 | |||||
| EV-to-FCF | 1.32 | |||||
| Price-to-Net-Current-Asset-Value | 0.62 | |||||
| Price-to-Net-Cash | 0.63 | |||||
| Earnings Yield (Greenblatt) % | 107.53 | |||||
| FCF Yield % | -49.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVIR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Atea Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2 | ||
| Beta | 0.77 | ||
| 3-Year Sharpe Ratio | -0.37 | ||
| 3-Year Sortino Ratio | -0.55 | ||
| Volatility % | 26.68 | ||
| 14-Day RSI | 58.42 | ||
| 14-Day ATR ($) | 0.125098 | ||
| 20-Day SMA ($) | 3.0685 | ||
| 12-1 Month Momentum % | -17.8 | ||
| 52-Week Range ($) | 2.75 - 4.145 | ||
| Shares Outstanding (Mil) | 85.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Atea Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Atea Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Atea Pharmaceuticals Inc Frequently Asked Questions
What is Atea Pharmaceuticals Inc(AVIR)'s stock price today?
The current price of AVIR is $3.20. The 52 week high of AVIR is $4.14 and 52 week low is $2.75.
When is next earnings date of Atea Pharmaceuticals Inc(AVIR)?
The next earnings date of Atea Pharmaceuticals Inc(AVIR) is 2025-05-14 Est..
Does Atea Pharmaceuticals Inc(AVIR) pay dividends? If so, how much?
Atea Pharmaceuticals Inc(AVIR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers